HRMY 📈 Harmony Biosciences Holdings - Overview

Harmony Biosciences Holdings, a commercial-stage pharmaceutical company, is dedicated to developing and commercializing innovative therapies for patients affected by rare and other neurological diseases in the United States. The company's product portfolio includes WAKIX, a proprietary molecule known as pitolisant, which boasts a novel mechanism of action designed to treat excessive daytime sleepiness in adult patients with narcolepsy. By targeting the histamine H3 receptor, WAKIX aims to address the underlying causes of excessive daytime sleepiness, providing a unique treatment option for patients with this debilitating condition.

Harmony Biosciences Holdings is also invested in the research and development of HBS-102, a melanin-concentrating hormone receptor 1 antagonist that targets MCH neurons. This molecule has the potential to address various neurological disorders, and the company is committed to exploring its therapeutic applications. With a strong focus on neuroscience and a dedication to improving patient outcomes, Harmony Biosciences Holdings is poised to make a significant impact in the pharmaceutical industry. The company's commitment to innovation and its patient-centric approach have earned it a reputation as a leader in the development of treatments for rare and neurological diseases.

Originally founded as Harmony Biosciences II, Inc. in 2017, the company underwent a name change to Harmony Biosciences Holdings, Inc. in February 2020. Headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences Holdings has established itself as a key player in the pharmaceutical sector, with a web presence at https://www.harmonybiosciences.com. The company's common stock is listed on the NASDAQ exchange under the ticker symbol HRMY, with the ISIN code US4131971040, and is classified under the GICS Sub Industry: Pharmaceuticals. As a publicly traded company, Harmony Biosciences Holdings is committed to transparency and accountability, providing investors and stakeholders with regular updates on its progress and achievements.